Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.37)
# 369
Out of 4,667 analysts
73
Total ratings
50%
Success rate
21.17%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Initiates: Outperform | $60 | $36.41 | +64.79% | 1 | Nov 20, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $103.48 | +20.80% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $62.15 | +68.95% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $746.49 | +57.40% | 5 | Oct 24, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $50 → $45 | $23.20 | +93.97% | 2 | Aug 7, 2024 | |
| MRNA Moderna | Maintains: In-Line | $120 | $36.72 | +226.80% | 4 | Jun 27, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $87.60 | -2.96% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $124.14 | +40.97% | 1 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $46.74 | +88.28% | 6 | Feb 27, 2024 | |
| BIIB Biogen | Maintains: Neutral | $324 → $276 | $156.80 | +76.02% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.35 | +1,392.54% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $76 → $39 | $0.29 | +13,133.80% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $288.40 | -19.56% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $70.07 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $88.93 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $27.60 | -23.91% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $2.88 | +698.61% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $12.22 | +1,945.83% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.78 | +1,186.34% | 1 | Feb 14, 2018 |
SpringWorks Therapeutics
Nov 20, 2024
Initiates: Outperform
Price Target: $60
Current: $36.41
Upside: +64.79%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $103.48
Upside: +20.80%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $62.15
Upside: +68.95%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $746.49
Upside: +57.40%
BridgeBio Pharma
Aug 7, 2024
Maintains: Outperform
Price Target: $50 → $45
Current: $23.20
Upside: +93.97%
Moderna
Jun 27, 2024
Maintains: In-Line
Price Target: $120
Current: $36.72
Upside: +226.80%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $87.60
Upside: -2.96%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $124.14
Upside: +40.97%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $46.74
Upside: +88.28%
Biogen
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $156.80
Upside: +76.02%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.35
Upside: +1,392.54%
Feb 17, 2021
Downgrades: Neutral
Price Target: $76 → $39
Current: $0.29
Upside: +13,133.80%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $288.40
Upside: -19.56%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $70.07
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $88.93
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $27.60
Upside: -23.91%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $2.88
Upside: +698.61%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $12.22
Upside: +1,945.83%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.78
Upside: +1,186.34%